YahooAugust 30, 2026 at 10:00 PM NYLast Month
Subsidised Access to Columvi® Now Available for Eligible Patients with Relapsed or Refractory DLBCL in Singapore
Columvi® (glofitamab) will be added to the Singapore Ministry of Health's (MOH) CDL and MAF List. Starting 1 September 2026, this milestone ensures that eligible Singaporeans and Permanent Residents will have subsidised access to the medication in public healthcare institutions.[1]
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
